GIPERTONIYA KASALLIGI VA OʻPKANING SURUNKALI OBSTRUKTIV KASALLIGI BOR BEMORLARDA TELMISARTANNING YURAKNING SISTOLIK VA DIASTOLIK DISFUNKSIYALARIGA TAʼSIRI

Xoltajiyev Xurshid Otabek oʻgʻli

Vol. 3 No. 4 (2025), Articles

Vol. 3 No. 4 (2025)

GIPERTONIYA KASALLIGI VA OʻPKANING SURUNKALI OBSTRUKTIV KASALLIGI BOR BEMORLARDA TELMISARTANNING YURAKNING SISTOLIK VA DIASTOLIK DISFUNKSIYALARIGA TAʼSIRI

Articles

Published 2025-04-26

Xoltajiyev Xurshid Otabek oʻgʻli⁺⁻

Xoltajiyev Xurshid Otabek oʻgʻli

Toshkent Tibbiyot Akademiyasi Kardiologiya mutaxassisligi birinchi kurs magistratura talabasi

PDF

DOI

Keywords

Gipertoniya kasalligi, surunkali obstruktiv o‘pka kasalligi, Telmisartan, sistolik disfunktsiya, diastolik disfunktsiya, yurak yetishmovchiligi, arterial gipertenziya, antigipertenziv preparatlar, yurak funksiyasini baholash, kardioprotektiv ta’sir, qon bosimini boshqarish, klinik tadqiqotlar

How to Cite

GIPERTONIYA KASALLIGI VA OʻPKANING SURUNKALI OBSTRUKTIV KASALLIGI BOR BEMORLARDA TELMISARTANNING YURAKNING SISTOLIK VA DIASTOLIK DISFUNKSIYALARIGA TAʼSIRI. (2025). Journal of Universal Science Research, 3(4), 249-253. https://universalpublishings.com/~niverta1/index.php/jusr/article/view/11112

Abstract

Ushbu maqolada gipertoniya kasalligi va o‘pkaning surunkali obstruktiv kasalligi (O‘SOK) bilan og‘rigan bemorlarda Telmisartanning yurakning sistolik va diastolik funksiyalariga ta’siri o‘rganildi. Tadqiqot davomida Telmisartan preparatining yurak mushaklarining qisqarish (sistolik) va bo‘shashish (diastolik) fazalariga bo‘lgan ijobiy terapevtik ta’siri aniqlangan

PDF

DOI

References

1. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. “Gipertoniya kasalligini tashxislash va davolash bo‘yicha klinik protokol”. Toshkent, 2021.

2. GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2024 Report.

3. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021; 42(36): 3599–3726.

4. Muxamedov M.M., Salimov A.S. "Ichki kasalliklar propedevtikasi". Toshkent: “Ilm Ziyo”, 2020.

5. Yuldashev M.X. va boshqalar. “Klinik terapiya”. Toshkent: Tibbiyot, 2019.

6. Messerli F.H., Bangalore S., Bavishi C., Rimoldi S.F. “Angiotensin receptor blockers in hypertension: to use or not to use?” Journal of the American College of Cardiology, 2018; 71(13): 1474–1482.

7. Ruilope L.M., Scholze J. “Telmisartan in the treatment of hypertension: current knowledge and future prospects.” Vascular Health and Risk Management, 2009; 5(1): 473–482.

8. Yusuf S., Teo K.K., Pogue J. et al. “Telmisartan, ramipril, or both in patients at high risk for vascular events.” New England Journal of Medicine, 2008; 358(15): 1547–1559.

9. Kasymova M.N. “Ichki kasalliklar klinikasi va farmakoterapiyasi.” Samarqand, 2021.

10. Jenkins J., Nanchahal J., et al. “The role of Telmisartan in cardiovascular and renal protection.” Current Medical Research and Opinion, 2020; 36(4): 621–630.

11. Tashkent Medical Academy. “Yurak yetishmovchiligi: zamonaviy diagnostika va davolash usullari.” O‘quv qo‘llanma, 2022.

12. Agabekov I.B., Abdurakhmanova G.U. “Kardiologiyada zamonaviy yondashuvlar.” Toshkent, 2018.

13. National Institute for Health and Care Excellence (NICE). “Hypertension in adults: diagnosis and management.” NICE guideline [NG136], 2019.

14. Rahimova D.I., Karimov B.B. “Gipertoniya kasalligida yurak funksiyasining buzilishi.” Tibbiyot fanlari jurnali, 2023; 1(3): 42–47.

15. Khan M.H., Ghali J.K. “Systolic and diastolic heart failure: pathophysiology, diagnosis, and treatment.” Journal of Clinical Hypertension, 2020; 22(7): 1190–1198.